68-Ga FAPI 46
Alternative Names: 68Ga-FAPi-46; [68Ga]FAPI-46Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator University of Heidelberg
- Developer SOFIE; University of California
- Class Antineoplastics; Imaging agents; Quinolines; Radioisotopes; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pancreatic cancer
- No development reported Breast cancer; Cholangiocarcinoma; Gastric cancer; Interstitial lung diseases; Ovarian cancer
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-0 development in Interstitial lung diseases(Diagnosis) in USA (IV)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Cholangiocarcinoma(Diagnosis, Late-stage disease) in Sweden (IV, Injection)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Gastric-cancer(Diagnosis, Late-stage disease) in Sweden (IV, Injection)